Cargando…

Response to “Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: Report of 5 cases”

Detalles Bibliográficos
Autores principales:	Lim, Ziying Vanessa, Kanagalingam, Jeevendra, Heng, Yee Kiat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Notes & Comments
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767934/ https://www.ncbi.nlm.nih.gov/pubmed/35071714 http://dx.doi.org/10.1016/j.jdcr.2021.09.044

Ejemplares similares

Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: Report of 5 cases
por: Rodríguez-Jiménez, Pedro, et al.
Publicado: (2021)

A case of reactivation of varicella–zoster virus after BNT162b2 vaccine second dose?
por: Santovito, Luca Spiro, et al.
Publicado: (2021)

Effectiveness of BNT162b2 against COVID-19 in adolescents
por: Powell, Annabel A, et al.
Publicado: (2022)

Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer
por: Ligumsky, Hagai, et al.
Publicado: (2022)

SARS-CoV-2 mRNA vaccination and subsequent herpes zoster: Possible immune reconstitution by mRNA vaccination
por: Ota, Mitsuhito
Publicado: (2022)

A case of varicella zoster virus meningitis following BNT162b2 mRNA COVID-19 vaccination in an immunocompetent patient
por: Maruki, Taketomo, et al.
Publicado: (2021)

Herpes zoster dermatitis in a COVID-19 vaccinated healthy man after 1 dose of varicella vaccine
por: Etaee, Farshid, et al.
Publicado: (2022)

The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus
por: Maldonado, M.D., et al.
Publicado: (2021)

Safety and BNT162b2 mRNA COVID-19 vaccination
por: Joob, Beuy, et al.
Publicado: (2021)

Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors
por: Waissengrin, Barliz, et al.
Publicado: (2021)

Varicella-Zoster Virus (VZV) Meningitis in an Immunocompetent Adult after BNT162b2 mRNA COVID-19 Vaccination: A Case Report
por: Medhat, R., et al.
Publicado: (2022)

Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT
por: Redjoul, Rabah, et al.
Publicado: (2021)

Beta SARS-CoV-2 variant and BNT162b2 vaccine effectiveness in long-term care facilities in France
por: Lefèvre, Benjamin, et al.
Publicado: (2021)

COVID-19 infection and BNT162b2 vaccine triggering sarcoid-like lesions in the same patient. Response to: Sarcoid-like reaction in a patient recovering from COVID-19 pneumonia
por: Grieco, Teresa, et al.
Publicado: (2022)

Varicella zoster virus reactivation and mRNA vaccines as a trigger
por: Lladó, Iñigo, et al.
Publicado: (2021)

SARS-CoV-2 messenger RNA vaccination during herpes zoster infection in an elderly man
por: Katayama, Sho, et al.
Publicado: (2022)

Zoster sine herpete following BNT162b2 mRNA COVID-19 vaccination in an immunocompetent patient
por: Tanizaki, Ryutaro, et al.
Publicado: (2022)

Adverse events after BNT162b2 mRNA COVID-19 vaccination in health care workers and medical students in Japan
por: Namiki, Takahiro, et al.
Publicado: (2022)

Reactivation of Varicella Zoster Virus after Vaccination for SARS-CoV-2
por: Psichogiou, Mina, et al.
Publicado: (2021)

Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies
por: Gressens, Simon B., et al.
Publicado: (2022)

Reassurance on bleeding and thrombotic events following second dose BNT162b2 and ChAdOx1 COVID-19 vaccines
por: Pavord, Sue, et al.
Publicado: (2023)

Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2)
por: Favresse, Julien, et al.
Publicado: (2021)

A case of herpes zoster ophthalmicus after third dose of Comirnaty (BNT162b2 mRNA) vaccine
por: Martora, Fabrizio, et al.
Publicado: (2022)

Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: Real-world evidence from healthcare workers in Japan
por: Saita, Mizue, et al.
Publicado: (2022)

Heterologous ChAdOx1-nCoV19–BNT162b2 vaccination provides superior immunogenicity against COVID-19
por: Richardson, Christopher D
Publicado: (2021)

Varicella-zoster virus encephalitis mimicking toxoplasmosis relapse
por: Marques, Inês Brás, et al.
Publicado: (2015)

Silent Reactivation of Varicella Zoster Virus in Pregnancy: Implications for Maintenance of Immunity to Varicella
por: Mourad, Mirella, et al.
Publicado: (2022)

Herpes zoster and alopecia areata following mRNA BNT162b2 COVID‐19 vaccine: Controversial immune effects
por: Martora, Fabrizio, et al.
Publicado: (2022)

Myelitis and Radiculitis Complicating Varicella-Zoster Virus Reactivation
por: Corrêa, Diogo Goulart, et al.
Publicado: (2020)

Tozinameran: Reactivation of varicella zoster virus: case report
Publicado: (2022)

Tozinameran: Varicella-zoster virus reactivation: case report
Publicado: (2022)

The Spectrum of Neurological Manifestations of Varicella–Zoster Virus Reactivation
por: Kennedy, Peter G. E.
Publicado: (2023)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Erythema nodosum triggered by BNT162b2 mRNA COVID-19 vaccine
por: Juddoo, Vanessa, et al.
Publicado: (2022)

Comment on Aldén et al. Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line. Curr. Issues Mol. Biol. 2022, 44, 1115–1126
por: Merchant, Hamid A.
Publicado: (2022)

Hemorrhagic herpes zoster duplex unilateralis in a patient taking clopidogrel
por: Miller, Austinn C., et al.
Publicado: (2023)

Vanishing spinal cord after varicella-zoster virus myelitis
por: Sepúlveda, María, et al.
Publicado: (2017)

Mercaptopurine/methotrexate/tozinameran: Varicella zoster virus reactivation: 2 case reports
Publicado: (2021)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

Patients with B-cell malignancies experience reduced antibody responses with class switching defect following BNT162b2 SARS-CoV-2 vaccination
por: Nakagama, Yu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cof8ek3jive5g22lbu4lvo3ms7